Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1064 | 937 | 1111 | 1188 | 1513 | 2363 |
Fund Return | 6.39% | -6.31% | 11.12% | 5.9% | 8.63% | 8.98% |
Place in category | 435 | 748 | 542 | 80 | 66 | 109 |
% in Category | 45 | 78 | 55 | 10 | 12 | 33 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
AXA Framlington Global Technology F | 1.28B | 15.22 | 3.30 | 18.41 | ||
AXA Framlington Global Technology a | 1.28B | 15.23 | 3.30 | 18.42 | ||
GB00B5LXGG05 | 1.16B | 25.55 | 9.92 | 16.64 | ||
AXA Global Distribution R Acc | 269.57M | 7.32 | -0.58 | 5.06 | ||
AXA Global Distribution R Inc | 269.57M | 7.31 | -0.58 | 5.14 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Janus Global Life Sciences Fund U G | 3.79B | 11.21 | 7.04 | 12.01 | ||
Wellington Global Health Care EquiG | 2B | 6.70 | 4.03 | 11.14 | ||
Global Health Care Fund W Acc GBP | 105.48M | 8.57 | 4.09 | 10.65 | ||
Adamant Medtech I GBP | 1.53B | 14.50 | 4.03 | 12.68 | ||
Pharmaceuticals Index Trust F Acc | 250.05K | 7.53 | 5.00 | 9.55 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Eli Lilly | US5324571083 | 8.97 | 779.90 | +1.58% | |
Novo Nordisk B | DK0062498333 | 6.59 | 626.5 | +6.33% | |
UnitedHealth | US91324P1021 | 5.68 | 502.56 | +0.49% | |
Merck&Co | US58933Y1055 | 4.70 | 98.49 | +0.45% | |
Thermo Fisher Scientific | US8835561023 | 4.38 | 521.78 | -0.43% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Strong Sell | Strong Sell | Neutral |
Technical Indicators | Strong Sell | Strong Sell | Sell |
Summary | Strong Sell | Strong Sell | Neutral |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review